IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial

–News Direct–

Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients.

IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/iq-ai-limited-shares-latest-progress-from-phase-i-glioblastoma-clinical-trial-206132431

IQ-AI Ltd

COMTEX_437041890/2655/2023-07-19T13:03:04